AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generated FY2025 revenue of $61.2 billion (+8.7%) and $17.8 billion in free cash flow, with Skyrizi and Rinvoq contributing about 42% of sales as the company offsets Humira's patent-expiry impact. Analysts expect AbbVie sales to reach $67.2 billion and net income to rise sharply to $14.6 billion this year, supported by immunology growth, pipeline prospects and its planned Apogee Therapeutics acquisition. Novo Nordisk posted FY2025 revenue of $48.2 billion (+6%) and nearly $16 billion of net income, but consensus expects FY2026 sales and net income to decline roughly 3% and 4%, respectively, amid GLP-1 pricing pressure and competition from Eli Lilly; it trades at 13.8x forward P/E versus AbbVie's 16.1x.

Analysis

ABBV’s near-term setup is less about absolute immunology growth than whether Skyrizi/Rinvoq can sustain enough volume and indication expansion to absorb both Humira erosion and IRA-driven net-price pressure. The market is likely to reward a 2026 earnings step-up if it is accompanied by durable 2027 guidance, but the quality of that growth matters: acquired pipeline costs, amortization, and milestone payments can make headline EPS growth materially less cash-accretive than it appears. The claimed APGE transaction should be treated as unverified until terms, financing, and expected dilution are confirmed; if real, it increases ABBV’s dependence on successful late-stage execution rather than reducing concentration risk.

NVO’s lower multiple embeds a potentially more important issue than a one-year earnings reset: obesity is transitioning from a supply-constrained market to a formulary- and efficacy-driven market. As payer access broadens, net realized price, persistence, and rebate intensity—not prescription growth alone—will determine earnings power. LLY is the principal beneficiary if superior efficacy translates into preferred-formulary status, while PBM/distributor economics at MCK, COR, and CAH can improve modestly as GLP-1 volumes rise but are unlikely to be a material earnings driver without a larger shift toward specialty distribution.

The consensus appears too favorable on ABBV’s apparent valuation discount versus growth and too punitive on NVO’s 2026 trough. ABBV deserves a higher discount rate if its earnings inflection is substantially dependent on a narrow immunology franchise and deal activity; NVO could rerate before reported growth recovers if weekly prescription trends, oral GLP-1 uptake, and gross-to-net trends stabilize. Over the next 1-3 months, earnings guidance and prescription/channel data matter most; over 6-18 months, formulary wins, clinical differentiation, and obesity pricing policy determine the relative winner.

Key Decisions for Investors

• Initiate a 3-6 month relative-value position: long NVO / short ABBV in equal beta-weighted dollars. Target 10-15% relative upside if NVO’s earnings-reset narrative bottoms while ABBV’s 2027 growth durability is questioned; exit if NVO cuts forward volume guidance or ABBV raises post-2026 immunology guidance with clear net-price support.
• Maintain or add LLY as the higher-quality obesity exposure on pullbacks rather than chase NVO solely on its lower multiple. The catalyst is formulary and prescription-share evidence over the next two quarterly reporting cycles; risk is a meaningful NVO oral-drug share gain or adverse LLY safety/tolerability data.
• For ABBV holders, use a defined-risk hedge around regulatory and guidance events via 6-month put spreads, financed where possible with upside call overwrites. The key falsifier for a bearish hedge is sustained Skyrizi/Rinvoq growth with stable gross-to-net metrics and no increase in integration-related costs.
• Do not treat MCK, COR, or CAH as direct GLP-1 beta trades. Monitor disclosed specialty-drug mix and working-capital trends; a trade becomes actionable only if distributors demonstrate that higher GLP-1 volume is lifting operating-margin dollars rather than merely revenue throughput.